BIEL: AI 评分 53/100 — AI 分析 (4月 2026)

BioElectronics Corporation develops and sells wearable neuromodulation devices for pain management and neurological conditions. The company's product line includes ActiPatch, Allay, Smart Insole, RecoveryRx, and HealFast, targeting both human and animal healthcare markets.

Key Facts: AI Score: 53/100 Sector: Healthcare

公司概况

概要：

BioElectronics Corporation is an electroceutical company focused on developing and marketing wearable neuromodulation devices for pain management and neurological conditions. Its product portfolio, including ActiPatch and Allay, caters to both human and animal healthcare markets, offering non-pharmaceutical alternatives for pain relief and tissue healing.

BIEL是做什么的？

BioElectronics Corporation, established in 2000 and headquartered in Frederick, Maryland, is an electroceutical company specializing in the development and commercialization of wearable neuromodulation devices. These devices are designed to alleviate pain and improve the quality of life for individuals suffering from neurological diseases and musculoskeletal conditions. The company's flagship product, ActiPatch, is a widely recognized therapy for musculoskeletal pain. Other key products include Allay, specifically designed for menstrual pain relief; Smart Insole, targeting heel pain; RecoveryRx, a pain management solution for medical professionals; and HealFast, a drug-free therapy for animals, addressing pain, swelling, and injuries in horses, cats, and dogs. BioElectronics distributes its products through a network of wholesale distributors, hospitals, clinics, and directly to consumers, ensuring broad market access. The company's focus on non-invasive, drug-free pain management positions it within the growing electroceuticals market, offering alternatives to traditional pharmaceutical interventions.

BIEL的投资论点是什么？

BioElectronics Corporation presents a compelling investment case centered on its innovative electroceutical devices and expanding market reach. The company's focus on non-pharmaceutical pain management solutions aligns with the increasing demand for safer, non-addictive therapies. With a gross margin of 73.3%, BioElectronics demonstrates strong potential for profitability as it scales its operations. Key growth catalysts include expanding distribution channels, securing regulatory approvals for new products, and increasing market penetration in both human and animal healthcare segments. However, the company's negative profit margin of -187.6% and reliance on OTC markets pose significant risks. Investors should closely monitor the company's ability to achieve profitability and navigate the challenges associated with OTC trading.

BIEL在哪个行业运营？

BioElectronics Corporation operates within the medical device industry, specifically in the electroceuticals sub-segment. This market is experiencing growth due to increasing demand for non-invasive, drug-free pain management solutions. The competitive landscape includes companies like ADMT, AIMLF, BGXX, CHMMF, and GVDI, some of which offer similar neuromodulation devices or alternative pain management therapies. The electroceuticals market is projected to grow as technological advancements and regulatory support increase, driving adoption of these innovative therapies. BioElectronics is positioned to capitalize on this trend with its established product line and distribution network.

Medical - Devices

Healthcare

BIEL有哪些增长机遇？

Expansion into New Therapeutic Areas: BioElectronics has the opportunity to expand its product line to address additional therapeutic areas beyond pain management, such as neurological disorders and wound healing. The market for neurological disorder treatments is substantial, with a global market size estimated at billions of dollars. By leveraging its existing neuromodulation technology, BioElectronics can develop new devices targeting these conditions, potentially increasing its revenue streams and market share. Timeline: 2-3 years for product development and regulatory approval.
Geographic Market Expansion: BioElectronics can pursue growth by expanding its market presence into new geographic regions, particularly in developing countries where access to traditional pain management therapies may be limited. These markets often have less stringent regulatory requirements, allowing for faster market entry. The global market for medical devices is expanding rapidly, driven by increasing healthcare expenditure and aging populations. Timeline: 1-2 years for market entry and distribution setup.
Strategic Partnerships and Acquisitions: BioElectronics can accelerate its growth through strategic partnerships and acquisitions. Collaborating with established medical device companies or acquiring complementary technologies can enhance its product portfolio and market reach. The medical device industry is characterized by consolidation, with larger companies acquiring smaller, innovative firms. Timeline: Ongoing, with potential deals occurring within the next 1-3 years.
Direct-to-Consumer Marketing and E-commerce: BioElectronics can increase sales and brand awareness by investing in direct-to-consumer marketing and expanding its e-commerce presence. Online sales of medical devices are growing rapidly, driven by increasing consumer adoption of e-commerce and the convenience of online shopping. By targeting consumers directly, BioElectronics can bypass traditional distribution channels and increase its profit margins. Timeline: 6-12 months for implementation and optimization.
Veterinary Market Expansion: BioElectronics can further penetrate the veterinary market with its HealFast product line. The market for animal healthcare products is growing, driven by increasing pet ownership and rising awareness of animal health and welfare. By expanding its distribution channels and marketing efforts in the veterinary market, BioElectronics can increase sales and establish itself as a leading provider of drug-free therapies for animals. Timeline: 1-2 years for market expansion and product development.

Gross Margin of 73.3% indicates strong potential for profitability as the company scales its operations.
The company operates in the electroceuticals market, a growing sector driven by demand for non-pharmaceutical pain management solutions.
Product portfolio includes ActiPatch, a recognized therapy for musculoskeletal pain, providing a foundation for revenue generation.
The company distributes its products through multiple channels, including wholesale distributors, hospitals, clinics, and direct to consumers, ensuring broad market access.
Beta of 2.03 suggests higher volatility compared to the overall market.

BIEL提供哪些产品和服务？

Develops wearable neuromodulation devices.
Offers ActiPatch for musculoskeletal pain therapy.
Provides Allay for menstrual pain therapy.
Markets Smart Insole for heel pain therapy.
Sells RecoveryRx for pain management in medical settings.
Distributes HealFast for pain relief in animals.

BIEL如何赚钱？

Develops and manufactures wearable neuromodulation devices.
Sells products through wholesale distributors, hospitals, and clinics.
Offers direct-to-consumer sales through online channels.

Individuals suffering from musculoskeletal pain.
Women experiencing menstrual pain.
Medical professionals seeking pain management solutions.
Pet owners and veterinarians treating animal injuries.

Proprietary neuromodulation technology.
Established brand recognition for ActiPatch.
Distribution network across multiple channels.
Focus on non-pharmaceutical pain management.

什么因素可能推动BIEL股价上涨？

Upcoming: Potential regulatory approvals for new products in development.
Ongoing: Expansion of distribution channels into new geographic markets.
Ongoing: Increasing adoption of electroceutical devices for pain management.
Ongoing: Strategic partnerships with established medical device companies.

BIEL的主要风险是什么？

Potential: Competition from established medical device companies.
Potential: Regulatory hurdles and compliance requirements.
Ongoing: Patent expiration and intellectual property risks.
Ongoing: Negative profit margin and limited financial resources.
Potential: Economic downturn affecting healthcare spending.

BIEL的核心优势是什么？

Proprietary neuromodulation technology
Established brand recognition for ActiPatch
Diverse product portfolio targeting multiple pain conditions
Distribution network across wholesale, hospitals, clinics, and direct-to-consumer channels

BIEL的劣势是什么？

Negative profit margin
Reliance on OTC markets
Limited financial resources for marketing and R&D
Dependence on a small number of key products

BIEL有哪些机遇？

Expansion into new therapeutic areas
Geographic market expansion
Strategic partnerships and acquisitions
Direct-to-consumer marketing and e-commerce growth

BIEL面临哪些威胁？

Competition from established medical device companies
Regulatory hurdles and compliance requirements
Patent expiration and intellectual property risks
Economic downturn affecting healthcare spending

BIEL的竞争对手是谁？

Adamas Pharmaceuticals, Inc. — Focuses on neurological disorders. — (ADMT)
Aium Engineering Corp. — Develops medical devices. — (AIMLF)
BioGate AG — Offers healthcare solutions. — (BGXX)
China Medical System Holdings Ltd. — Pharmaceutical company. — (CHMMF)
GVD Communications, Inc. — Telecommunications and healthcare. — (GVDI)

Key Metrics

MoonshotScore: 53/100

Company Profile

CEO: Kelly A. Whelan
Headquarters: Frederick, US
Founded: 2004

AI Insight

AI analysis pending for BIEL

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does BioElectronics Corporation do?

BioElectronics Corporation is an electroceutical company that develops, manufactures, and markets wearable neuromodulation devices. These devices are designed to provide non-invasive, drug-free pain relief for various conditions, including musculoskeletal pain, menstrual pain, and heel pain. The company's product line includes ActiPatch, Allay, Smart Insole, RecoveryRx, and HealFast, targeting both human and animal healthcare markets. BioElectronics sells its products through wholesale distributors, hospitals, clinics, and directly to consumers, offering an alternative to traditional pharmaceutical interventions for pain management.

What do analysts say about BIEL stock?

As of 2026-03-16, there is no available analyst coverage for BioElectronics Corporation (BIEL). The company's OTC listing and limited financial disclosure may contribute to the lack of analyst coverage. Investors should conduct their own due diligence and consider the company's financial performance, growth prospects, and risk factors before making any investment decisions. Key valuation metrics, such as price-to-earnings ratio and price-to-sales ratio, may not be readily available or reliable due to the company's financial situation.

What are the main risks for BIEL?

BioElectronics Corporation faces several risks, including competition from established medical device companies, regulatory hurdles and compliance requirements, patent expiration and intellectual property risks, negative profit margin and limited financial resources, and potential economic downturn affecting healthcare spending. The company's reliance on OTC markets also poses additional risks, such as limited financial disclosure, higher price volatility, and lower trading volume. Investors should carefully consider these risks before investing in BIEL.